# Study and Evaluation Scheme

# of

# M. Pharm Program (Pharmacology)

[Applicable w.e.f. Academic Session - 2021-22] Choice Based Credit System, (CBCS)



TEERTHANKER MAHAVEER UNIVERSITY N.H.-24, Delhi Road, Moradabad, Uttar Pradesh-244001 Website: <u>www.tmu.ac.in</u>

1



The program of study for M. Pharm-Choice Based Credit System (CBCS) shall extend over a period of four semesters (two academic years). The curricula and syllabi for the program shall be prescribed from time to time by Pharmacy Council of India, New Delhi.

# Program/Course credit structure

#### Theory and Laboratory courses

Courses are broadly classified as Theory and Practical. Theory courses consist of lecture (L) and Practical (P) courses consist of hours spent in the laboratory.

- i. Credits (C) for a course is dependent on the number of hours of instruction per week in that course, and is obtained by using a multiplier of one (1) for lecture and a multiplier of half (1/2) for practical (laboratory) hours. Thus, for example, a theory course having four lectures per week throughout the semester carries a credit of 4.
- ii. Similarly, a practical having four laboratory hours per week throughout semester carries a credit of 2. The contact hours of seminars, assignments and research work shall be treated as that of practical courses for the purpose of calculating credits. i.e., the contact hours shall be multiplied by 1/2.
- iii. Similarly, the contact hours of journal club, research work presentations and discussions with the supervisor shall be considered as theory course and multiplied by 1.

#### Minimum credit requirements

The minimum credit points required for the award of M. Pharm. degree is 100. However, based on the credit points earned by the students under the head of co-curricular activities, a student shall earn a maximum of 105 credit points (Table 1).

Semester	Credit Points
I	26
11	26
111	26
1V	20
Co-curricular Activities (Attending Conference, Scientific Presentations and Other Scholarly Activities)	Minimum=02 Maximum=07*
Total Credit Points	Minimum=100 Maximum=105*
Credit Points for Co-curricular Activities	PRINCIPAL PRINCIPAL

Table 1: Semester wise credits distribution

# Course of study

The course of study for M. Pharm specializations shall include Semester wise Theory & Practical as given in Table -2.1 to 2.4. The number of hours to be devoted to each theory and practical course in any semester shall not be less than that shown in Table 2.1 to 2.4.

		M. Pharm. (Pharmacology) Semester I				
Category	Course Code	Course	Credit Hours	Credit Points	Hrs./w k	Marks
CC-1	MPL101T	Modern Pharmaceutical Analytical Techniques	4	4	4	100
CC-2	MPL102T	Advanced Pharmacology-I	4	4	4	100
CC-3	MPL103T	Pharmacological and Toxicological Screening Methods-I	4	4	4	100
CC-4	MPL104T	Cellular and Molecular Pharmacology	4	4	4	100
SEC-1	MPL105P	Pharmacology Practical I	12	6	12	150
SEC-2	MPL106	Seminar/Assignment	7	4	7	100
		Total	35	26	35	650

# Table 2.1: Course of study for M. Pharm. (Pharmacology)

CC- Core Course, SEC-Skill Enhancement Course

Value Added Course (VAC)

Category	Course Code	Course	Credit Hours	Internal	External	Marks
VAC-1	TMUPS-101	Managing Self	00	50	50	100

		Semester II				
Category	Course Code	Course	Credit Hours	Credit Points	Hrs./w k	Marks
CC-5	MPL201T	Advanced Pharmacology II	4	4	4	100
CC-6	MPL202T	Pharmacological and Toxicological Screening Methods-II	4	4	4	100
CC-7	MPL203T	Principles of Drug Discovery	4	4	4	100
CC-8	MPL204T	Clinical Research and Pharmacovigilance	4	4	4	100
SEC 3	MPL205P	Pharmacology Practical II	12	6	12	150
	MPL206	Seminar/Assignment	7	4	7	100
SEC-4		Total	35	26	35	650

CC- Core Course, SEC-Skill Enhancement Course

MORADASI

PRINCIPAL

Category	Course Code	Course	Credit Hours	Internal	External	Marks
VAC-2	TMUPS- 201	Managing work and others	00	50	50	100
VAC-3	TMUPS- 202	Introduction to SPSS	00	50	50	100
VAC-4	TMUPS- 203	Communication Skills and Technical Writing	00	50	50	100

#### Value Added Course (VAC)

#### Table 2.2: Course of study for M. Pharm. (Common for All Specializations)

5		M. Pharm. III Semester (Common for All Specializations)		
Category	Course Code	Course	Credit Hours	Credit Points
	MRM301T	Research Methodology and Biostatistics*	4	4
	MRM302T	Pharmacoeconomics		
DSEC-	MRM303T	Blockchain Technology in Pharmaceutical Industry		
1**	MRM304T	Digital Therapeutics and Curative Therapies	3	3
	MRM305T	Biosimilars		
SEC-5	MRM306	Journal Club	1	1
SEC-6	MRM307	Discussion / Presentation (Proposal Presentation)	2	2
SEC-7	MRM308	Research Work	28	14
	MRM309T	Entrepreneurship Skill Development		
GEC-1***	MRM310T	Intellectual Property Rights	7	,
	MRM311T	Business Model Innovation	4	-
	MRM312T	Principles of Management		
		Total	40	26

DSEC-Discipline Specific Elective Course, SEC-Skill Enhancement Course, GEC- General Elective Course

\*Non University Examination

\*\*One course to be opted as electives out of four

\*\*\* One course to be opted as general electives out of four

Table 2.3: Course of study for M. Pharm. (Common for All Specializations)

		M. Pharm. IV Semester		1
Category	Course Code	Course	Credit Hours	Credit Points
SEC-8	MRM401	Journal Club	1	1
SEC-9	MRM402	Discussion / Presentation (Final Presentation)	3	3
SEC-10	MRM403	Research Work & Colloquium	31	16
360-10		Total	35 JANE	R COLLZO

Scanned with CamScanner

PBHNCIPAL

 Table 2.4: Guidelines for Awarding Credit Points for Co-curricular Activities

 (Attending Conference, Scientific Presentations and Other Scholarly Activities)

Maximum Credit Points Eligible / Activity
2
1
2
1
2

International Journal: The Editorial Board outside India.

\*\*The credit points assigned for extracurricular and or co-curricular activities shall be given by the Principals of the colleges and the same shall be submitted to the University.

## **Examinations/Assessments**

#### Sessional Exams

Two sessional exams shall be conducted for each theory / practical course as per the schedule fixed by the college(s). The scheme of question paper for theory and practical sessional examinations is given in the table. The average marks of two sessional exams shall be computed for internal assessment.

#### End semester examinations

The End Semester Examinations for each theory and practical course through semesters I to IV shall be conducted by the Teerthanker Mahaveer University except for non-university courses for which examinations shall be conducted by the subject experts at college level and the marks/grades shall be submitted to the university.

# Promotion and award of grades

A student shall be declared PASS and eligible for getting grade in a course of M. Pharm. programme if he/she secures at least 50% marks in that particular course including internal assessment.



# Carry forward of marks

In case a student fails to secure the minimum 50% in any Theory or Practical course, then he/she shall reappear for the end semester examination of that course. However, his/her marks of the Internal Assessment shall be carried over and he/she shall be entitled for grade obtained by him/her on passing.

# Allowed to keep terms (ATKT)

A student shall be eligible to carry forward all the courses of I and II semesters till the III semester examinations. However, he/she shall not be eligible to attend the courses of IV semester until all the courses of I, II and III semesters are successfully completed. A student shall be eligible to get his/her CGPA upon successful completion of the courses of I to IV semesters within the stipulated time period as per the norms.

#### Grading of performances

#### Letter grades and grade points allocations

Based on the performances, each student shall be awarded a final letter grade at the end of the semester for each (Table 5). A learner who remains absent for any end semester examination shall be assigned a letter grade of AB and a corresponding grade point of zero. He/she should reappear for the said evaluation/examination in due course.

Percentage of Marks Obtained	Letter Grade	Grade Point	Performance
90.00-100.00	0	10	Outstanding
80.00-89.99	Α	9	Excellent
70.00-79.99	B	8	Good
60.00-69.99	C	7	Fair
50.00-59.99	D	6	Average
less than 50	F	0	Fail
Absent	AB	0	Fail

Table 5: Letter grades and grade points equivalent to Percentage of marks and performances

### The Semester grade point average (SGPA)

The performance of a student in a semester is indicated by a number called 'Semester Grade Point Average' (SGPA). The SGPA is the weighted average of the grade points obtained in all the courses by the student during the semester. For example, if a student takes five courses (Theory/Practical) in a semester with credits C1, C2, C3 and C4 and the student's grade points in these courses are G1, G2, G3 and G4, respectively, and then students' SGPA is equal to:



$$SGPA = \frac{C_1G_1 + C_2G_2 + C_3G_3 + C_4G_4}{C_1 + C_2 + C_3 + C_4}$$

The SGPA is calculated to two decimal points. It should be noted that, the SGPA for any semester shall take into consideration the F and ABS grade awarded in that semester. For example if a learner has a F or ABS grade, the SGPA shall then be computed as:

$$SGPA = \frac{C_1G_1 + C_2G_2 + C_3G_3 + C_4^*Zero}{C_1 + C_2 + C_3 + C_4}$$

#### **Cumulative Grade Point Average (CGPA)**

The CGPA is calculated with the SGPA of all the IV semesters to two decimal points and is indicated in final grade report card/final transcript showing the grades of all IV semesters and their courses. The CGPA shall reflect the failed status in case of F grade(s), till the course(s) is/are passed. When the course(s) is/are passed by obtaining a pass grade on subsequent examination(s) the CGPA shall only reflect the new grade and not the fail grades earned earlier. The CGPA is calculated as:

$$SGPA = \frac{C_1S_1 + C_2S_2 + C_3S_3 + C_4S_4}{C_1 + C_2 + C_3 + C_4}$$

where C1, C2, C3,.... is the total number of credits for semester I,II,III,.... and S1,S2, S3,.... is the SGPA of semester I,II,III,.....

### **Declaration of class**

The class shall be awarded on the basis of CGPA as follows:

First Class with Distinction	CGPA of. 7.50 and above	
	CCPA of 6 00 to 7.49	
First Class	CGIAGIOLOGIA	
	CCPA of 5.00 to 5.99	
Second Class	COLA OF DIGO CO COLA	

Duration for completion of the program of study



Scanned with CamScanner

7

The duration for the completion of the program shall be fixed as double the actual duration of the program and the students have to pass within the said period, otherwise they have to get fresh Registration.

# **Revaluation/Retotalling of answer papers**

There is no provision for revaluation of the answer papers in any examination. However, the candidates can apply for retotalling by paying prescribed fee.

### Re-admission after break of study

Candidate who seeks re-admission to the program after break of study has to get the approval from the university by paying a condonation fee.





[Applicable w.e.f. Academic Session - 2021-22 till revised] [Framed under the Revised Regulation of the Master of Pharmacy (M. Pharm) Degree Programme regulations 3(a) of 2014 given by PCI]



# **TEERTHANKER MAHAVEER UNIVERSITY** N.H.-24, Delhi Road, Moradabad, Uttar Pradesh-244001 Website: <u>www.tmu.ac.in</u>

9



### PROGRAM SPECIFIC OUTCOMES: M. PHARM (PHARMACOLOGY)

### After completion of the course the students will be

10

**PSO-1:** Understanding the application of pharmacological information of active chemical entity (Drug) present in a medicine that is used for diagnosis, prevention, treatment/cure of a disease.

**PSO-2:** Illustrating pharmacodynamic and pharmacokinetic investigation to evaluate the efficacy and safety of drugs in animal models.

**PSO-3:** Demonstrating mechanism of action of drug in preclinical research involved in Neurotransmission and Neurohumoral transmission apply in biomedical research.

**PSO-4:** Practicing animals handling of different species / strains along with their breeding and maintenance as per CPCSEA/international Guidelines/Good laboratory practice (GLP).

**PSO-5:** Identifying the *in vivo*, *in vitro*, and other possible animal alternative models for screening of new substances.

**PSO-6:** Developing the core concept of establishing toxicological profile of a new drug while evaluating during research.



COURSE CODE: MPL 101T	M. Pharm- Semester-I	L-4 T-0
	Modern Pharmaceutical Analytical Techniques	P-0 C-4
Course Outcomes:	<ul> <li>On completion of the course, the students will be:</li> <li>CO1-Understanding the basic concepts and advances in analytical techniques and theoretical skills of the analytical instruments.</li> <li>CO2-Applying advanced analytical instrumental techniques for Identification, characterization and quantification of drugs.</li> <li>CO3-Performing quantitative &amp; qualitative analysis of drugs using various analytical instruments in single and combination dosage forms.</li> <li>CO4- Evaluating given samples with respect to official standards.</li> </ul>	
Course Conte	nts:	
Unit-1:	UV-Visible spectroscopy: Introduction, Theory, Laws, Instrumentation associated with UV-Visible spectroscopy, Choice of solvents and solvent effect and Applications of UV-Visible spectroscopy, Difference/ Derivative spectroscopy. <b>IR spectroscopy:</b> Theory, Modes of Molecular vibrations, Sample handling, Instrumentation of Dispersive and Fourier - Transform IR Spectrometer, Factors affecting vibrational frequencies and Applications of IR spectroscopy, Data Interpretation. <b>Spectroflourimetry:</b> Theory of Fluorescence, Factors affecting fluorescence (Characteristics of drugs that can be analysed by fluorimetry), Quenchers, Instrumentation and Applications of fluorescence spectrophotometer. <b>Flame emission spectroscopy and</b> <b>Atomic absorption spectroscopy:</b> Principle, Instrumentation, Interferences and Applications	10hr
Unit-2:	NMR spectroscopy: Quantum numbers and their role in NMR, Principle, Instrumentation, Solvent requirement in NMR, Relaxation process, NMR signals in various compounds, Chemical shift, Factors influencing chemical shift, Spin-Spin coupling, Coupling constant, Nuclear magnetic double resonance, Brief outline of principles of FT- NMR and 13C NMR. Applications of NMR spectroscopy.	10hr
Unit-3:	Mass Spectroscopy: Principle, Theory, Instrumentation of Mass Spectroscopy, Different types of ionization like electron impact, chemical, field, FAB and MALDI, APCI, ESI, APPI Analysers of Quadrupole and Time of Flight, Mass fragmentation and its rules, Meta stable ions, Isotopic peaks and Applications of Mass spectroscopy.	10hr
Unit-4:	Chromatography: Principle, apparatus, instrumentation, chromatographic parameters, factors affecting resolution, isolation of drug from excipients, data interpretation and applications of the following: a) Thin Layer chromatography b) High Performance Thin Layer Chromatography c) Ion exchange chromatography d) Column chromatography e) Gas chromatography f) High Performance Liquid chromatography	10hr
11	PRINCI	PAL

g) Ultra High Performance Liquid chromatography         h) Affinity chromatography         i) Gel Chromatography.         i) Gel Chromatography.         i) Gel Chromatography.         i) Gel Chromatography.         ii) Gel Chromatography.         iii) Gel Chromatography.         iiiiii (Chromatography.)         iiiiiiiii (Chromatography.)         iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	-						
Unit-5:       Electrophoresis: Principle, Instrumentation, Working conditions, factors affecting separation and applications of the following: a) Paper electrophoresis b) Gel electrophoresis c) Capillary electrophoresis d) Zone electrophoresis e) Moving boundary electrophoresis f) Iso electric focusing       10hr         Unit-5:       N ray Crystallography: Production of X rays, Different X ray methods, Bragg's law, Rotating crystal technique, X ray powder technique, Types of crystals and applications of X-ray diffraction.       10hr         Unit-6:       Potentiometry: Principle, working, Ion selective Electrodes and Application of Potentiometry. Thermal Techniques: Principle, thermal transitions and Instrumentation (Heat flux and power-compensation and designs), Modulated DSC, Hyper DSC, experimental parameters (sample preparation, experimental conditions, derivative differential thermal analysis (DTA): Principle, instrumentation, and disadvantages, pharmaceutical applications. derivative differential thermal analysis (DTA): Principle, instrumentation, factors affecting results, advantage and disadvantages, pharmaceutical applications, derivative differential thermal analysis (DDTA). TGA: Principle, instrumentation, factors affecting results, advantage and disadvantages, pharmaceutical Applications.       10hr         Text Books:       1       Spectroscopy of Organic Compounds, 2nd edn., P.S/Kalsi, Wiley estern Ltd., Delhi.       1         1       Spectrometric Identification of Organic compounds - Robert M Silverstein, Sixth edition, John Wiley & Sons, 2004.       1       Nieman, 5 th edition, CBS publishers. 4. Practical Pharmaceutical formulation, FLBS, 1991.       1         3       Instrumental methods of analysis – Willard			<ul><li>g) Ultra High Performance Liquid chromatography</li><li>h) Affinity chromatography</li><li>i) Gel Chromatography.</li></ul>				
N ray Crystallography: Production of X rays, Different X ray methods, Bragg's law, Rotating crystal technique, X ray powder technique, Types of crystals and applications of X-ray diffraction.         Potentiometry: Principle, working, Ion selective Electrodes and Application of Potentiometry. Thermal Techniques: Principle, thermal transitions and Instrumentation (Heat flux and power-compensation and designs), Modulated DSC, Hyper DSC, experimental parameters (sample preparation, experimental conditions, calibration, heating and cooling rates, resolution, source of errors) and their influence, advantage and disadvantages, pharmaceutical applications. Differential Thermal Analysis (DTA): Principle, instrumentation and advantage and disadvantages, pharmaceutical applications, derivative differential thermal analysis (DDTA). TGA: Principle, instrumentation, factors affecting results, advantage and disadvantages, pharmaceutical applications.         Text Books:         1. Spectroscopy of Organic Compounds, 2nd edn., P.S/Kalsi, Wiley estern Ltd., Delhi.         2. Textbook of Pharmaceutical Analysis, KA.Connors, 3 rd Edition, John Wiley & Sons, 1982         Reference Books:         1. Spectrometric Identification of Organic compounds - Robert M Silverstein, Sixth edition, John Wiley & Sons, 2004.         2. Principles of Instrumental Analysis – Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5 th edition, Eastern press, Bangalore, 1998.         3. Instrumental methods of analysis – Willards, 7th edition, CBS publishers, 4. Practical Pharmaceutical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.         4. Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.       5. Quantitative Analysis of Drugs		Unit-5:	<b>Electrophoresis:</b> Principle, Instrumentation, Working conditions, factors affecting separation and applications of the following: a) Paper electrophoresis b) Gel electrophoresis c) Capillary electrophoresis d) Zone electrophoresis e) Moving boundary electrophoresis f) Iso electric focusing	10hr			
Potentiometry: Principle, working, Ion selective Electrodes and Application of Potentiometry. Thermal Techniques: Principle, thermal transitions and Instrumentation (Heat flux and power-compensation and designs), Modulated DSC, Hyper DSC, experimental parameters (sample preparation, experimental conditions, calibration, heating and cooling rates, resolution, source of errors) and their influence, advantage and disadvantages, pharmaceutical applications. Differential Thermal Analysis (DTA): Principle, instrumentation and advantage and disadvantages, pharmaceutical applications, derivative differential thermal analysis (DDTA). TGA: Principle, instrumentation, factors affecting results, advantage and disadvantages, pharmaceutical applications.         Text Books:         1. Spectroscopy of Organic Compounds, 2nd edn., P.S/Kalsi, Wiley estern Ltd., Delhi.         2. Textbook of Pharmaceutical Analysis, KA.Connors, 3 rd Edition, John Wiley & Sons, 1982         Reference Books:         1. Spectrometric Identification of Organic compounds - Robert M Silverstein, Sixth edition, John Wiley & Sons, 2004.         2. Principles of Instrumental Analysis - Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5 th edition, Eastern press, Bangalore, 1998.         3. Instrumental methods of analysis – Willards, 7th edition, CBS publishers. 4. Practical Pharmaceutical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.         4. Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.         5. Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.         6. Pharmaceutical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel.			X ray Crystallography: Production of X rays, Different X ray methods, Bragg's law, Rotating crystal technique, X ray powder technique, Types of crystals and applications of X-ray diffraction.				
<ol> <li>Text Books:         <ol> <li>Spectroscopy of Organic Compounds, 2nd edn., P.S/Kalsi, Wiley estern Ltd., Delhi.</li> <li>Textbook of Pharmaceutical Analysis, KA.Connors, 3 rd Edition, John Wiley &amp; Sons, 1982</li> </ol> </li> <li>Reference Books:         <ol> <li>Spectrometric Identification of Organic compounds - Robert M Silverstein, Sixth edition, John Wiley &amp; Sons, 2004.</li> <li>Principles of Instrumental Analysis - Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5 th edition, Eastern press, Bangalore, 1998.</li> <li>Instrumental methods of analysis – Willards, 7th edition, CBS publishers. 4. Practical Pharmaceutical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.</li> <li>Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.</li> <li>Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.</li> <li>Pharmaceutical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel. Dekker Series.</li> </ol> </li> </ol>		Unit-6:	<b>Potentiometry:</b> Principle, working, Ion selective Electrodes and Application of Potentiometry. <b>Thermal Techniques:</b> Principle, thermal transitions and Instrumentation (Heat flux and power-compensation and designs), Modulated DSC, Hyper DSC, experimental parameters (sample preparation, experimental conditions, calibration, heating and cooling rates, resolution, source of errors) and their influence, advantage and disadvantages, pharmaceutical applications. <b>Differential Thermal Analysis (DTA):</b> Principle, instrumentation and advantage and disadvantages, pharmaceutical applications, derivative differential thermal analysis (DDTA). TGA: Principle, instrumentation, factors affecting results, advantage and disadvantages, pharmaceutical applications.	10hr			
<ol> <li>Spectroscopy of Organic Compounds, 2nd edn., P.S/Kalsi, Wiley estern Ltd., Delhi.</li> <li>Textbook of Pharmaceutical Analysis, KA.Connors, 3 rd Edition, John Wiley &amp; Sons, 1982</li> <li>Reference Books:         <ol> <li>Spectrometric Identification of Organic compounds - Robert M Silverstein, Sixth edition, John Wiley &amp; Sons, 2004.</li> <li>Principles of Instrumental Analysis - Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5 th edition, Eastern press, Bangalore, 1998.</li> <li>Instrumental methods of analysis – Willards, 7th edition, CBS publishers. 4. Practical Pharmaceutical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.</li> <li>Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.</li> <li>Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.</li> <li>Pharmaceutical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel. Dekker Series.</li> </ol> </li> </ol>	Te	xt Books:					
<ol> <li>Reference Books:         <ol> <li>Spectrometric Identification of Organic compounds - Robert M Silverstein, Sixth edition, John Wiley &amp; Sons, 2004.</li> <li>Principles of Instrumental Analysis - Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5 th edition, Eastern press, Bangalore, 1998.</li> <li>Instrumental methods of analysis – Willards, 7th edition, CBS publishers. 4. Practical Pharmaceutical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.</li> <li>Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.</li> <li>Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.</li> <li>Pharmaceutical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel. Dekker Series.</li> </ol> </li> </ol>	1. 2.	Spectroscopy of Organic Compounds, 2nd edn., P.S/Kalsi, Wiley estern Ltd., Delhi. Textbook of Pharmaceutical Analysis, KA.Connors, 3 rd Edition, John Wiley & Sons, 1982					
<ol> <li>Spectrometric Identification of Organic compounds - Robert M Silverstein, Sixth edition, John Wiley &amp; Sons, 2004.</li> <li>Principles of Instrumental Analysis - Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5 th edition, Eastern press, Bangalore, 1998.</li> <li>Instrumental methods of analysis – Willards, 7th edition, CBS publishers. 4. Practical Pharmaceutical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.</li> <li>Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.</li> <li>Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.</li> <li>Pharmaceutical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel. Dekker Series.</li> </ol>	Re	ference Boo	ks:				
<ol> <li>Principles of Instrumental Analysis - Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5 th edition, Eastern press, Bangalore, 1998.</li> <li>Instrumental methods of analysis – Willards, 7th edition, CBS publishers. 4. Practical Pharmaceutical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.</li> <li>Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.</li> <li>Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.</li> <li>Pharmaceutical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel. Dekker Series.</li> </ol>	1.	Spectrome	tric Identification of Organic compounds - Robert M Silverstein, Sixth & Sons, 2004.	edition,			
<ol> <li>Instrumental methods of analysis – Willards, 7th edition, CBS publishers. 4. Practical Pharmaceutical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.</li> <li>Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.</li> <li>Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.</li> <li>Pharmaceutical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel. Dekker Series.</li> </ol>	2.	Principles 5 th edition	of Instrumental Analysis - Doglas A Skoog, F. James Holler, Timothy A. N Bastern press Bangalore, 1998	lieman,			
<ul> <li>Pharmaceutical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.</li> <li>Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.</li> <li>Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.</li> <li>Pharmaceutical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel. Dekker Series.</li> </ul>	3.	Instrument	al methods of analysis – Willards, 7th edition, CBS publishers. 4. P	ractical			
<ol> <li>Delhi, 1997.</li> <li>Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.</li> <li>Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.</li> <li>Pharmaceutical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel. Dekker Series.</li> </ol>		Pharmaceu	tical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publisher	s, New			
<ol> <li>Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.</li> <li>Pharmaceutical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel. Dekker Series.</li> </ol>	Δ	Organic St	/. bectroscopy - William Kemp, 3rd edition, ELBS, 1991.				
<ol> <li>Pharmaceutical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel. Dekker Series.</li> </ol>	5.	Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers New Delhi, 1997.					
	6.	Pharmaceu Series.	tical Analysis - Modern Methods – Part B - J W Munson, Vol 11, Marcel.	Dekker			



Course Code:	M. Pharm- Semester-I	L-4
MPL102T	ADVANCED PHARMACOLOGY - I (MPL102T)	P-0
Course Outcomes:	On completion of the course, the students will be: <b>CO1-Understanding the basic knowledge in the field of pharmacology</b> pertaining to the drugs and its therapeutic applications for the treatment of various diseases. <b>CO2-Analysing the mechanism of drug actions at cellular and molecular level.</b> <b>CO3 -Evaluating the adverse effects, contraindications and clinical uses of drugs</b> used in treatment of various diseases	
	General Pharmacology	1
Unit-1:	<ul> <li>a) Pharmacokinetics: The dynamics of drug absorption, distribution, biotransformation and elimination. Concepts of linear and non-linear compartment models. Significance of Protein binding.</li> <li>b) Pharmacodynamics: Mechanism of drug action and the relationship between drug concentration and effect. Receptors, structural and functional families of receptors, quantitation of drug receptors interaction and elicited effects.</li> </ul>	12hr
Unit-2:	<ul> <li>Neurotransmission <ul> <li>a) General aspects and steps involved in neurotransmission.</li> <li>b) Neurohumoral transmission in autonomic nervous system (Detailed study about neurotransmitters- Adrenaline and Acetyl choline).</li> <li>c) Neurohumoral transmission in central nervous system (Detailed study about neurotransmitters- histamine, serotonin, dopamine, GABA, glutamate and glycine].</li> <li>d) Non adrenergic non cholinergic transmission (NANC). Co-transmission <i>Systemic Pharmacology</i></li> <li>a) A detailed study on pathophysiology of diseases, mechanism of action, pharmacology and toxicology of existing as well as novel drugs used in the following systems Autonomic Pharmacology</li> <li>b) Parasympathomimetics and lytics, sympathomimetics and lytics, agents affecting neuromuscular junction</li> </ul> </li> </ul>	12hr
Unit-3:	<ul> <li>Central nervous system Pharmacology</li> <li>a) General and local anaesthetics</li> <li>b) Sedatives and hypnotics, drugs used to treat anxiety.</li> <li>c) Depression, psychosis, mania, epilepsy, neurodegenerative diseases.</li> <li>d) Narcotic and non-narcotic analgesics.</li> </ul>	12hr
	Cardiovascular Pharmacology	
Unit-4:	Diuretics, antihypertensives, antiischemics, anti- arrhythmics, drugs for heart failure and hyperlipidemia. Hematinics, coagulants, anticoagulants, fibrinolytics and anti- platelet drugs	12hr

MORACOS

Unit-5:	Autocoid Pharmacology The physiological and pathological role of Histamine, Serotonin, Kinins Prostaglandins Opioid autocoids. Pharmacology of antihistamines, 5HT antagonists.	12hr
---------	--	------

#### **Text Books:**

- 1. K D. Tripathi. Essentials of Medical Pharmacology.
- 2. A Complete Textbook of Medical Pharmacology by Dr. S.K Srivastava published by APC Avichal Publishing Company
- 3. Basic and Clinical Pharmacology by B.G Katzung.

#### **Reference Books:**

- 1. The Pharmacological Basis of Therapeutics, Goodman and Gillman'sPrinciples of Pharmacology. The Pathophysiologic basis of drug Therapy by David E
- 2. Golan, Armen H, TashjianJr, Ehrin J, Armstrong, April W, Armstrong, Wolters, Kluwer-Lippincott Williams & Wilkins Publishers.
- 3. Hand book of Clinical Pharmacokinetics by Gibaldi and Prescott.
- 4. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew
- 5. B.C.Yu. Graham Smith. Oxford textbook of Clinical Pharmacology. Avery Drug Treatment
- 6. Dipiro Pharmacology, Pathophysiological approach.
- 7. Green Pathophysiology for Pharmacists.
- 8. Robbins & Cortan Pathologic Basis of Disease, 9 th Ed. (Robbins Pathology)
- 9. Modern Pharmacology with Clinical Applications, Craig Charles R. & Stitzel Robert E., Lippincott Publishers.
- 10. Clinical Pharmacokinetics & Pharmacodynamics : Concepts and Applications
- 11. Malcolm Rowland and Thomas N.Tozer, Wolters Kluwer, Lippincott Williams & Wilkins Publishers.
- 12. Applied biopharmaceutics and Pharmacokinetics, Pharmacodynamics and Drug metabolism for industrial scientists.
- 13. Modern Pharmacology, Craig CR. &Stitzel RE, Little Brown & Company.

CACOLLER

BINCIPA

Course Code: MPL103T	M. Pharm- Semester-I PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS - I	L-4 T-0 P-0
Course Out	comes:	
Course Cont	On completion of the course, the students will be: CO1-Understandingandevaluatingtherecent experimental techniques in the discovery and development. CO2- Understanding the maintenance of laboratory animals as per the guideling various in-vitro and in-vivo preclinical evaluation processes. CO3-Applying the various screening methods involved in the drug discovery pro- ents:	e drug nes, and cess
	Laboratory Animals Common laboratory animals: Description, handling and	
Unit-1:	applications of different species and strains of animals. Transgenic animals: Production, maintenance and applications Anaesthesia and euthanasia of experimental animals. Maintenance and breeding of laboratory animals. CPCSEA guidelines to conduct experiments on animals Good laboratory practice. Bioassay-Principle, scope and limitations and methods	12 hr
Unit-2:	Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models. General principles of preclinical screening. CNS Pharmacology: behavioural and muscle co-ordination, CNS stimulants and depressants, anxiolytics, anti- psychotics, anti-epileptics and nootropics. Drugs for neurodegenerative diseases like Parkinsonism, Alzheimers and multiple sclerosis. Drugs acting on Autonomic Nervous System.	12hr
Unit-3:	Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models. Respiratory Pharmacology: anti-asthmatics, drugs for COPD and anti allergics. Reproductive Pharmacology: Aphrodisiacs and antifertility agents Analgesics, anti-inflammatory and antipyretic agents. Gastrointestinal drugs: anti-ulcer, anti- emetic, anti- diarrheal and laxatives.	12 hr
Unit-4:	Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models. Cardiovascular Pharmacology: antihypertensives, antiarrythmics, antianginal, antiatherosclerotic agents and diuretics. Drugs for metabolic disorders like anti- diabetic, antidyslipidemic agents. Anti-cancer agents. Hepatoprotective screening methods.	12hr
Unit-5:	Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models. Iimmunomodulators, Immunosuppressants and immunostimulants General principles of immunoassay: theoretical basis and optimization of immunoassay, heterogeneous and homogenous immunoassay systems. Immunoassay methods evaluation; protocol outline, objectives and preparation. Immunoassay for digoxin and insulin Limitations of animal experimentation and alternate animal experiments. Extrapolation of in vitro data to preclinical and preclinical to humans	12 hr
Text Book	s:	
I. Bio	logical standardization by J.H. Bull D.J. Finney and R.O. Goodwin	tet
15	PRIHEIPA	9.J

1.144 J

2. Fundamentals of experimental Pharmacology by M.N.Ghosh

3. Preclinical evaluation of new drugs by S.K. Gupta

#### **Reference Books:**

- 1. Screening methods in Pharmacology by Robert Turner. A
- 2. Evaluation of drugs activities by Laurence and Bachrach
- 3. Methods in Pharmacology by Arnold Schwartz.
- 4. Pharmacological experiment on intact preparations by Churchill Livingstone Drug discovery and Evaluation by Vogel H.G.
- 5. Experimental Pharmacology by R.K.Goyal.
- Handbook of Experimental Pharmacology, S. K. Kulkarni Practical Pharmacology and Clinical Pharmacy, SK.Kulkarni, 3 rd Edition.
- 7. David R.Gross. Animal Models in Cardiovascular Research, 2 nd Edition, Kluwer Academic Publishers, London, UK.
- 8. Screening Methods in Pharmacology, Robert A.Turner.
- 9. Rodents for Pharmacological Experiments, Dr. Tapan Kumar chatterjee.
- 10. Practical Manual of Experimental and Clinical Pharmacology by BikashMedhi (Author), Ajay Prakash (Author)

\* Latest editions of all the suggested books are recommended.

ANFER COLLE

CELEULAR AND MULECULAR PHARMACOLOGY	P-0 C-4
(tcomes:	
On completion of the course, the students will be: <b>CO-1</b> Understanding the fundamental knowledge on the structure and functions of cellular components. <b>CO-2</b> Appreciating the interaction of cellular components with drugs and applying the knowledge in drug discovery process. <b>CO-3</b> They would have learnt to explain the molecular pathways affected by drugs. <b>CO-4</b> Applying the molecular pharmacology and biomarkers in drug discovery process.	
tents:	
Cell biology Structure and functions of cell and its organelles Genome organization. Gene expression and its regulation, importance of siRNA and micro RNA, gene mapping and gene sequencing Cell cycles and its regulation. Cell death– events, regulators, intrinsic and extrinsic pathways of apoptosis. Necrosis and autophagy	12 hr
Cell signalling	
Intercellular and intracellular signalling pathways. Classification of receptor family and molecular structure ligand gated ion channels; G-protein coupled receptors, tyrosine kinase receptors and nuclear receptors. Secondary messengers: cyclic AMP, cyclic GMP, calcium ion, inositol 1, 4, 5-trisphosphate, (IP3), NO, and diacylglycerol. Detailed study of following intracellular signalling pathways: cyclic AMP signalling pathway, mitogen-activated protein kinase (MAPK) signalling, Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling pathway	12 hr
Principles and applications of genomic and proteomic tools DNA electrophoresis, PCR (reverse transcription and real time), micro array technique, SDS page, ELISA and western blotting, Recombinant DNA technology Basic principles of recombinant DNA technology-Restriction enzymes, various types of vectors. Applications of recombinant DNA technology. Gene therapy- Various types of gene transfer techniques, clinical applications	12 hr
and recent advances in gene merupy: <b>Pharmacogenomics</b> Cloning of disease gene. Genetic variation and its role in health/ pharmacology Polymorphisms affecting drug metabolism Genetic variation in drug transporters	12 h
	On completion of the course, the students will be: CO-1 Understanding the fundamental knowledge on the structure and functions of cellular components. CO-2 Appreciating the interaction of cellular components with drugs and applying the knowledge in drug discovery process. CO-3 They would have learnt to explain the molecular pathways affected by dirugs. CO-4 Applying the molecular pharmacology and biomarkers in drug discovery process. tents: Cell biology Structure and functions of cell and its organelles Genome organization. Gene expression and its regulation, importance of siRNA and micro RNA, gene mapping and gene sequencing Cell cycles and its regulators, intrinsic and extrinsic pathways of apoptosis. Necrosis and autophagy. <i>Cell signalling</i> Intercellular and intracellular signalling pathways. Classification of receptor family and molecular structure ligand gated ion channels; G-protein coupled receptors, tyrosine kinase receptors and nuclear receptors. <i>Secondary messengers:</i> cyclic AMP, cyclic GMP, calcium ion, inositol 1, 4, 5-trisphosphate, (IP3), NO, and diacylglycerol. Detailed study of following intracellular signalling pathways: cyclic AMP signalling pathway principles and applications of genomic and proteomic tools DNA electrophoresis, PCR (reverse transcription and real time), micro array technique, SDS page, ELISA and western blotting, Recombinant DNA technology Basie principles of recombinant DNA technology-Restriction enzymes, various types of vectors. Applications of recombinant DNA technology. Gene therapy- Various types of gene transfer techniques, clinical applications and recent advances in gene therapy. <i>Pharmacogenomics</i> Cloning of disease gene. Genetic variation and its role in health/ pharmacology Polymorphisms affecting drug metabolism Genetic variation in drug transporters

Scanned with CamScanner

	<ul> <li>Genetic variation in G protein coupled receptors Applications of proteomics science: Genomics, proteomics, metabolomics, functionomics, nutrigenomics <i>Immunotherapeutics:</i> Types of immunotherapeutics, humanisation antibody therapy, Immunotherapeutics in clinical practice.</li> <li>a. Cell culture techniques</li> <li>Basic equipments used in cell culture lab. Cell culture media, various types of cell culture, general procedure for cell cultures; isolation of cells, subculture, cryopreservation, characterization of</li> </ul>	
Unit-5:	cells and their application. Principles and applications of cell viability assays, glucose uptake assay, Calcium influx assays Principles and applications of flow	12
	cytometry	
	b. Biosimilars	
Text Books	s:	1
1. The	Cell, A Molecular Approach. Geoffrey M Cooper.	
2. Pha L. V	rmacogenomics: The Search for Individualized Therapies. Edited by J. Licinio a Vong	and M -
Reference	Books:	

- 1. Handbook of Cell Signaling (Second Edition) Edited by Ralph A. et.al
- 2. Molecular Pharmacology: From DNA to Drug Discovery. John Dickenson et.al
- 3. Basic Cell Culture protocols by CherilD.Helgason and Cindy L.Miller
- 4. Basic Cell Culture (Practical Approach ) by J. M. Davis (Editor)
- 5. Animal Cell Culture: A Practical Approach by John R. Masters (Editor)
- 6. Current porotocols in molecular biology vol I to VI edited by Frederick M.Ausuvel et al.



COURSE CODE:	M. Pharm- Semester-I	L-0 T-0
MPL105P	PHARMACOLOGY PRACTICAL - I	P-12 C-6
Course Outc	omes:	
	On completion of the course, the students will be:	ny animale
	<b>CO2:</b> Dreating the technique of blood Sempling and route of dr	iy anniais
	administration	ug
	CO3: Analysing drugs and Pharmaceuticals	
	<b>CO4:</b> Evaluating drugs in various animal models	
Course Cont	ent	
	1. Analysis of pharmacopoeial compounds and their formulation	ons by UV
	Vis spectrophotometer.	
-	2. Simultaneous estimation of multi component containing form	ulations by
	UV spectrophotometry.	
	3. Experiments based on HPLC.	
	4. Experiments based on Gas Chromatography.	
	5. Estimation of riboflavin/quinine sulphate by fluorimetry.	
	6. Estimation of sodium/potassium by flame photometry.	
	1. Handling of laboratory animals.	
	2. Various routes of drug administration.	•
	3. Techniques of blood sampling, anaestnesia and eutr	ianasia ol
	A Eunctional observation bottomy toats (modified Imagin toat)	
	5 Evaluation of CNS stimulant depressant anxiogenics and	anvialutia
	anticonvulsant activity	anxiorytic,
	6. Evaluation of analgesic, anti-inflammatory local anesthetic	mydriatic
	and miotic activity.	, myunane
	7. Evaluation of diuretic activity.	
	8. Evaluation of antiulcer activity by pylorus ligation method.	
	9. Oral glucose tolerance test.	
+	10. Isolation and identification of DNA from various sources	(Bacteria,
	Cauliflower, onion, Goat liver).	
	11. Isolation of RNA from yeast.	
	12. Estimation of proteins by Braford/Lowry's in biological samp	les.
	13. Estimation of RNA/DNA by UV Spectroscopy.	
	14. Gene amplification by PCR.	
	15. Protein quantification Western Blotting.	
	17. Call viability and μ (MTT)	icosidase).
116.32 PD 5.79	17. Cell viability assays (MT17/Trypan blue/SRB).	
	19. DNA damage study by Comet assay	
	20. Apoptosis determination by fluorescent imaging studies	
	21. Pharmacokinetic studies and data analysis of drugs studies.	
	routes of administration using software's	y different
	22. Enzyme inhibition and induction activity	
	23. Extraction of drug from various biological samples and set	Inat
	drugs in biological fluids using different analytical technic	unation of
	in our grout minus using unreferre analytical techniques	10 mg



19

Reference B	ooks
	<ol> <li>CPCSEA, OECD, ICH, USFDA, Schedule Y, EPA guidelines,</li> <li>Fundamentals of experimental Pharmacology by M.N.Ghosh</li> <li>Handbook of Experimental Pharmacology by S.K. Kulkarni.</li> <li>Drug discovery and Evaluation by Vogel H.G.</li> <li>Spectrometric Identification of Organic compounds - Robert M Silverstein,</li> <li>Principles of Instrumental Analysis - Doglas A Skoog, F. James Holler, Timothy A. Nieman,</li> <li>Vogel's Text book of quantitative chemical analysis - Jeffery, Basset Mendham, Denney,</li> <li>Basic Cell Culture protocols by Cheril D. Helgason and Cindy L.Mille</li> <li>Basic Cell Culture (Practical Approach ) by J. M. Davis (Editor)</li> <li>Animal Cell Culture: A Practical Approach by John R. Master (Editor)</li> <li>Practical Manual of Experimental and Clinical Pharmacology by BikashMedhi (Author), Ajay Prakash (Author) Jaypee brothers medical publishers Pvt. Ltd</li> </ol>

20

٠.



COURSE CODE:	M. Pharm- Semester-II	L-4
MPL201T	ADVANCED PHARMACOLOGY - II	T-0
	Comme O	P-0
	Course Outcomes:	<u>C-4</u>
	pertaining the basic knowledge in the field of pharmacology	
12	treatment of use	
	CO2-Analysing the masks	
	level.	
	CO3 -Evaluating the adverse effects	
1	drugs used in treatment of various diseases	
	Course Contents:	
	Endocrine Pharmacology Molecular and collular	
Unit 1.	hormones such as growth hormone prolacting the station of	12hr
Unit-1:	hormones Anti-thyroid drugs Oral hypotheses	
	contraceptives, Corticosteroids, Drugs affecting calcium agents, Oral	
	Chemotherapy Cellular and molecular mechanism of actions and	
Unit-2:	of antimicrobial agents such as B-lactams aminoglycosides minol	12hr
	Macrolide antibiotics. Antifungal, antiviral, and anti-TB drugs	
	Chemotherapy Drugs used in Protozoal Infections Drugs used in the treatment	101
	of Helminthiasis Chemotherapy of cancer Immunopharmacology Cellular and	1211
Unit-3:	biochemical mediators of inflammation and immune response. Allergic or	
	hypersensitivity reactions. Pharmacotherapy of asthma and COPD	
	Immunosuppressants and Immunostimulants	
	GIT Pharmacology Antiulcer drugs, Prokinetics, antiemetics, anti-diamheal	12h-
	and drugs for constipation and irritable bowel syndrome	1211
Unit-4:	Chronopharmacology Biological and circadian rhythms, applications of	
	chronotherapy in various diseases like cardiovascular disease, diabetes	
	asthma and peptic ulcer.	
	Free radicals Pharmacology Generation of free radicals, role of free radicals	12hr
	in etiopathology of various diseases such as diabetes, neurodegenerative	
Unit-5:	diseases and cancer. Protective activity of certain important antioxidant	
	Recent Advances in Treatment: Alzheimer's disease, Parkinson's disease,	
	Cancer, Diabetes mellitus	
	Text Books	
	1. A Complete Textbook of Medical Pharmacology by Dr. S.K Srivastava	
1	published by APC Avichal Publishing Company.	
	2. KD. Tripathi. Essentials of Medical Pharmacology	
	3. Principles of Pharmacology. The Pathophysiologic basis of drug Therapy	
1	by David E Golan, Armen H, TashjianJr, EhrinJ, Armstrong, April W,	
	Armstrong, Wolters, Kluwer-Lippincott Williams & Wilkins Publishers	
1	References Books	
1	The Pharmacological basis of therapeutics- Goodman and Gill man's	
12	2. Principles of Pharmacology. The Pathophysiologic basis of drug therapy	
t	by David E Golan et al.	1
3	Basic and Clinical Flathacology by B.O -Raizung	EGE
	E B	X
	PBINCIP	ALT
	1ª	

4. Pharmacology by H.P. Rang and M.M. Dale.

5. Hand book of Clinical Pharmacokinetics by Gibaldi and Prescott.

6. Text book of Therapeutics, drug and disease management by E T. Herfindal and Gourley.

7. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C.Yu.

8. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists

9. Robbins &Cortan Pathologic Basis of Disease, 9 th Ed. (Robbins Pathology)

ANAVEEN CA

RINCIE

COUDan	M. Pharm- Semester-II	L-4
COURSE		T-0 D 0
MPL202T	PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS-II	C-4
	Course Outcomes:	
	On completion of the course, the students will be:	
	CO1- Understanding and evaluating the recent experimental techniques in the	
	drug discovery, development and importance of ethical and regulatory	
	requirements for toxicity studies.	
	CO2-Understanding the maintenance of laboratory animals as per inc	
	guidelines, and various in-vitro and in-vivo preclinical and toxicological	
	evaluation processes.	
	CO3-Applying the various screening methods involved in the drug discovery	
	process and Demonstrate the practical skills required to conduct and	
	preclinical toxicity studies	
	Course Contents:	12hr
	Basic definition and types of toxicology (general, incentinistic, regulatory and	
Unit-1:	descriptive) Regulatory guidelines for conducting tonely statute	
	(CLP) History concept and its importance in drug development	
	(GLP) History, concept and its importance in and gueroup	12hr
	Acute, sub-acute and chrome- oral, dermal and instantion, dermal irritation &	
Unit-2:	DECD guidelines. Acute eye innation, skin etailon- importance and methods	
	dermal toxicity studies. Test tien characterization important	
	In regulatory toxicology studies Male reproductive toxicity studies, female	12hr
	Reproductive toxicology studies, man reproductive toxicology studies, man reproductive studies (segment I and segment III), teratogenicity studies	
	reproductive studies (segment 1 and 19	
Unit-3:	(segment 11) Genotoxicity studies (atoms studies) In vivo carcinogenicity	8
	Micronucleus and Chromosonian ao training	
	Studies	12hr
	IND enabling studies (into studies needed for IND submission. Safety	
	industry perspective, list of endine concepts and importance of safety	1
Unit-4:	pharmacology studies ongin, constant respiratory safety pharmacology	,
	pharmacology. Tier? GL renal and other studies	
	HERG assay. Herz-Gi, renar and evaluation in preclinical studies, saturation	1 12h
	Toxicokinetics- Toxicokinetic entropy of toxicokinetic studies. Alternative	e
Unit-5:	kinetics Importance and appreciation	
	methods to animal toxicity testing.	
	Text Books	
	1. Drugs from discovery to approve a rd Edition, Lower and Bryan	
	2. Animal Models in Toxicology, 5 th and 7	
	WEERC	OLIEN
	( Styles	102
	13	X
	PRINC	IPAL

#### **References Books**

1. Hand book on GLP, Quality practices for regulated non-clinical research and development (<u>http://www.who.int/tdr/publications/documents/glp-handbook.pdt</u>).

Schedule Y Guideline: drugs and cosmetics (second amendment) rules, 2005, ministry of health and family welfare (department of health) New Delhi
 OECD test guidelines.

4. Principles of toxicology by Karen E. Stine, Thomas M. Brown.

5. Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinform ation/guidances/ucm073246.pdf)

PRINCIPA

Locat

COURSI CODE: MPL2037	M. Pharm- Semester-II PRINCIPLES OF DRUG DISCOVERY	L-4 T-0 P-0
	Course Outcomes: CO1- Understanding the importance of the role of genomics, proteomics and bioinformatics in drug discovery CO2- Understanding and Explain various targets for drug discovery. CO3 evaluation of various lead seeking method and lead optimization CO4 Applying the various computer aided drug design in drug discovery Course Contents:	C-4
Unit-1:	An overview of modern drug discovery process: Target identification, target validation, lead identification and lead Optimization. Economics of drug discovery. Target Discovery and validation-Role of Genomics, Proteomics and Bioinformatics. Role of Nucleic acid microarrays, Protein microarrays, Antisense technologies, siRNAs, antisense oligonucleotides, Zinc finger proteins. Role of transgenic animals in target validation	12hr
Unit-2:	Lead Identification- combinatorial chemistry & high throughput screening, in silico lead discovery techniques, Assay development for hit identification. Protein structure Levels of protein structure, Domains, motifs, and folds in protein structure. Computational prediction of protein structure: Threading and homology modelling methods. Application of NMR and X-ray crystallography in protein structure prodiction	12hr
Unit-3:	Rational Drug Design Traditional vs rational drug design, Methods followed in traditional drug design, High throughput screening, Concepts of Rational Drug Design, Rational Drug Design Methods: Structure and Pharmacophore based approaches Virtual Screening techniques: Drug likeness screening, Concept of pharmacophore mapping and pharmacophore based Screening.	12hr
Unit-4:	Molecular docking: Rigid docking, flexible docking, manual docking; Docking based screening. De novo drug design. Quantitative analysis of Structure Activity Relationship History and development of QSAR, SAR versus QSAR, Physicochemical parameters, Hansch analysis, Fee Wilson analysis and relationship between them.	12hr
Unit-5:	QSAR Statistical methods – regression analysis, partial least square analysis (PLS) and other multivariate statistical methods. 3D-QSAR approaches like COMFA and COMSIA Prodrug design-Basic concept, Prodrugs to improve patient acceptability, Drug solubility, Drug absorption and distribution, site specific drug delivery and sustained drug action. Rationale of prodrug design and practical consideration of prodrug design	12hr
	<ul> <li>Text Books</li> <li>1. Abby L .Parrill. M . Rami Reddy. Rational Drug Design. Novel Methodology and Practical Applications. ACS Symposium Series; American Chemical Society: Washington, DC, 1999.</li> <li>2. J. Rick Turner. New drug development design, methodology and, analysis. John Wiley &amp; Sons, Inc., New Jersey.</li> </ul>	
		(A)

**References Books** 1. Mouldy Sioud. Target Discovery and Validation Reviews and Protocols: Volume 2 Emerging Molecular Targetsand Treatment Options. 2007 Humana Press Inc. 2. Darryl León. Scott Markelln. Silico Technologies in Drug Target Identification and Validation. 2006 by Taylor and Francis Group, LLC. 3. Johanna K. DiStefano. Disease Gene Identification. Methods and Protocols. Springer New York Dordrecht Heidelberg London. 4. Hugo Kubiny. QSAR: Hansch Analysis and Related Approaches. Methods and Principles in Medicinal Chemistry. Publisher Wiley-VCH 5. Klaus Gubernator, Hans-Joachim Böhm. Structure-Based Ligand Design. Methods and Principles in Medicinal Chemistry. Publisher Wiley-VCH. WANEER CO Lath Likes PRINCIPA 26

CODE: CODE:         M. Pharm-Semester-II         T-4 T-4           MPL204T         CLINICAL RESEARCH AND PHARMACOVIGILANCE         T-4 C-4           Course Outcomes: CO1- Understanding the regulatory requirements for conducting clinical trial. CO2- Understanding the types of clinical trial designs and Explain the responsibilities of key players involved in clinical trials. CO3- Applying the safety monitoring, reporting and close-out activities in clinical trials         Image: CO4- Course Contents:           Course Contents:         Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH- GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process         I2 hr           Unit-1:         Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Coordinator, Sponsor, Contract Research Organization and its management         I2 hr           Unit-3:         Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predicability assessment, Management of adverse drug reactions; Terminologies of ADR.         I2 hr           Unit-4:         Basic aspect, terminologies and establishing Pharmacovigilance entres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacovigilance	COVID		I.4
CDDE: MPL204T       CLINICAL RESEARCH AND PHARMACOVIGILANCE       1-0- C-4         Course Outcomes: COI - Understanding the regulatory requirements for conducting clinical trial. CO2 - Understanding the types of clinical trial designs and Explain the responsibilities of key players involved in clinical trials. CO3 - Applying the safety monitoring, reporting and close-out activities in clinical trials       1         CO 4 - Evaluation Pharmacovigilance, detect new adverse drug reactions and their assessment, reporting of ADR.       1         Course Contents:       Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process       12 hr         Unit-1:       Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management       12 hr         Unit-3:       Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance entres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilitie	COURSE	M. Pharm- Semester-II	L-4 T 0
Course Outcomes:       C-4         COI- Understanding the regulatory requirements for conducting clinical trial.       C-4         COI- Understanding the types of clinical trial designs and Explain the responsibilities of key players involved in clinical trials.       CO-4         COI- Understanding the safety monitoring, reporting and close-out activities in clinical trials.       CO-4         COI- Understanding the safety monitoring, reporting and close-out activities in clinical trials.       CO-4         Course Contents:       Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process: Structure and content of an Informed Consent Process: Ethical Principles governing informed consent process:       12 hr         Unit-1:       Clinical Trials: Types and Design Experimental Study-RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study       12 hr         Unit-2:       Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management       12 hr         Unit-3:       Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance Centre	MPL 204T	CLINICAL DESEADOR AND DUADMACOVICILANCE	1-0 D 0
Unit-3:         Course Outcomes: CO1- Understanding the regulatory requirements for conducting clinical trial. CO2- Understanding the types of clinical trial designs and Explain the responsibilities of key players involved in clinical trials. CO3- Applying the safety monitoring, reporting and close-out activities in clinical trials         CO3- Applying the safety monitoring, reporting and close-out activities in clinical trials           CO4 - Evaluation Pharmacovigilance, detect new adverse drug reactions and their assessment, reporting of ADR.         12 hr           Course Contents:         Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH- GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process         12 hr           Unit-2:         Clinical Trials: Types and Design Experimental Study-RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Cohort, Case Control, Cross sectional Clinical Trial Study Conditioner, Sponsor, Contract Research Organization and its management         12 hr           Unit-3:         Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods, Severity and seriousness assessment, Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.         12 hr	MI L2041	SERVICAL RESEARCH AND PHARMACOVIGILANCE	F-0
Coll - Understanding the regulatory requirements for conducting clinical trial.         COl - Understanding the types of clinical trial designs and Explain the responsibilities of key players involved in clinical trials.         CO3 - Applying the safety monitoring, reporting and close-out activities in clinical trials         CO4 - Evaluation Pharmacovigilance, detect new adverse drug reactions and their assessment, reporting of ADR.         Course Contents:         Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process         Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, 12 hr Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study         Unit-2:       Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management         Unit-3:       Drig Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment, redictability and preventability assessment, Management of Adverse drug reactions; Terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring prog		Course Outcomer	C-4
CO2- Understanding the regulatory requirements for conducting elimical trial.         CO2- Understanding the types of clinical trial designs and Explain the responsibilities of key players involved in clinical trials.         CO3- Applying the safety monitoring, reporting and close-out activities in clinical trials.         CO4- Evaluation Pharmacovigilance, detect new adverse drug reactions and their assessment, reporting of ADR.         Course Contents:         Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process         Clinical Trials: Types and Design Experimental Study-RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management         Unit-3:       Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring porgramme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharma		CO1-Understandi ut	
<ul> <li>Color Understanding the types of clinical trial designs and Explain the responsibilities of key players involved in clinical trials.</li> <li>CO3- Applying the safety monitoring, reporting and close-out activities in clinical trials</li> <li>CO 4- E-Valuation Pharmacovigilance, detect new adverse drug reactions and their assessment, reporting of ADR.</li> <li>Course Contents:</li> <li>Regulatory Perspectives of Clinical Trials: Origin and Principles of 12 hr International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process</li> <li>Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study</li> <li>Unit-2: Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management</li> <li>Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance enters in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacosi, Community Pharmacoist and Clinical Pharmacovigilance</li> <li>Unit-4:</li> <li>Unit-4:</li> <li>Unit-4:</li> <li>Wethods, ADR reporting and tools used in Pharmacovigilance International drug monitoring programme, W</li></ul>		CO2 Understanding the regulatory requirements for conducting clinical trial.	
CO3- Applying the safety monitoring, reporting and close-out activities in clinical trials         CO3- Applying the safety monitoring, reporting and close-out activities in clinical trials         CO 4- Evaluation Pharmacovigilance, detect new adverse drug reactions and their assessment, reporting of ADR.         Course Contents:         Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process         Clinical Trials: Types and Design Experimental Study-RCT and Non RCT, 12 hr Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study         Unit-2:       Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management         Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance entres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacovigilance contres in Hospitals, Industry and National programmes reporting and Clinical Pharmacovi		responsibilities of the types of clinical trial designs and Explain the	
<ul> <li>Couse Applying the safety monitoring, reporting and close-out activities in clinical trials</li> <li>CO 4- Evaluation Pharmacovigilance, detect new adverse drug reactions and their assessment, reporting of ADR.</li> <li>Course Contents:         <ul> <li>Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process: Ethical principles governing informed consent process</li> <li>Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management</li> <li>Clinical Trial Documentation- Guidelines to the preparation of documents, Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR, Basic aspects, terminologies and establishiment of Pharmacovigilance entres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacovigilance Centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacovigilance. Spontaneous reporting Pharmacovigilance International lensification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Repor</li></ul></li></ul>		CO3 Analysis of key players involved in clinical trials.	
C0 4- Evaluation Pharmacovigilance, detect new adverse drug reactions and their assessment, reporting of ADR.       Course Contents:         Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process: Structure and content of an Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process       12 hr         Unit-1:       Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management       12 hr         Unit-3:       Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.       12 hr         Unit-4:       Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance entres in Hospitals, Industry and National programmes related		clinical trials	
their assessment, reporting of ADR.         Course Contents:         Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process         Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management         Unit-2:       Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.         Unit-4:       Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring. Pharmacovigilance in India and international aspects, WHO international drug monitoring safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacovigilance         Unit-4:       Methods, ADR reporting and tools used in Pharmacovigilance International classifi		CO 4- Evaluation Pharmacovigilance, detect new adverse drug reactions and	
Course Contents:         Image: Course Contents:           Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH-ICHP)         12 hr           Unit-1:         GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process         12 hr           Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study         12 hr           Unit-2:         Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management         12 hr           Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.         12 hr           Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clin		their assessment, reporting of ADR.	
Regulatory Perspectives of Clinical Trials: Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH- GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process12 hrUnit-1: Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management12 hrUnit-3: Unit-3:Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.12 hrUnit-4: Unit-4:Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacovigilance12 hrUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International elassification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational		Course Contents:	
International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process         Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management         Unit-2:       Clinical Trial Documentation- Guidelines to the preparation of documents, Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.         Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance      12 hr         Unit-4:       Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance, Spontaneous reporting system and Reporting to regulatory aut		Regulatory Perspectives of Clinical Trials: Origin and Principles of	12 hr
Unit-1:       GCP) guidelines Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process         Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management       12 hr         Unit-2:       Clinical Trial Documentation- Guidelines to the preparation of documents, Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.       12 hr         Unit-4:       Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacovigilance       12 hr         Unit-5:       Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporti		International Conference on Harmonization - Good Clinical Practice (ICH-	
Unit-1:       Guidelines for Biomedical Research and Human Participant Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process         Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management       12 hr         Unit-2:       Clinical Trial Documentation- Guidelines to the preparation of documents, Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.         Unit-4:       Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacovigilance       12 hr         Unit-5:       Wethods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Ari	11.14.1	GCP) guidelines Ethical Committee: Institutional Review Board Ethical	
ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process       12 hr         Unit-2:       Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management       12 hr         Unit-3:       Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance entres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacovigilance       12 hr         Unit-5:       Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, S	Unit-1:	Guidelines for Biomedical Research and Human Participant Schedule Y	
Unit-3:       Consent Process Ethical principles governing informed consent process         Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study       12 hr         Unit-2:       Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management       12 hr         Unit-3:       Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.       12 hr         Unit-4:       Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance       12 hr         Unit-4:       Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous r		ICMR Informed Consent Process: Structure and content of an Informed	
Unit-1:Clinical Trials: Types and Design Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management12 hrUnit-2:Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.12 hrUnit-4:Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance12 hrUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International elassification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.12 hr<		Consent Process Ethical principles governing informed consent process	
Unit-2:DescriptionTeam Roles and responsibilities of Clinical Trial StudyTeam Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management12 hrUnit-3:Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.12 hrUnit-4:Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacovigilance12 hrUnit-4:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.12 hr		Clinical Trials: Types and Design Experimental Study. BCT and Nen BCT	12 hr
Unit-2:Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its managementUnit-3:Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance12 hrUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.		Observation Study: Cohort Case Control Cross sectional Clinical Trial Study:	12 11
<ul> <li>Unit-2: Team Roles and responsibilities of Clinical Trial Personnel: investigator, Study Coordinator, Sponsor, Contract Research Organization and its management</li> <li>Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.</li> <li>Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacovigilance</li> <li>Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.</li> </ul>	Unit 2.	Team Roles and remonsibilities of Clinical Trial Descende Lowerington	
Study Coordinator, Sponsor, Contract Research Organization and its managementUnit-3:Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical PharmacovigilanceUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted 	Cunt-2:	Study Coordinates Second Control Prisi Personnel: Investigator,	
Unit-3:Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.12 hrUnit-4:Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacovigilance12 hrUnit-4:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.12 hr		Study Coordinator, Sponsor, Contract Research Organization and its	
Unit-3:Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance12 hrUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.12 hr			
Unit-3:Preparation of protocol, investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance12 hrUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.12 hr		Clinical Irial Documentation- Guidelines to the preparation of documents,	12 hr
Unit-3:Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance12 hrUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.12 hr		Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical	
Unit-4:Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance12 hrUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.VigiFlow, Statistical methods for evaluating medication safety data.	Unit-3:	Study Report Clinical Trial Monitoring Safety Monitoring in CT Adverse	
Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance12 hrUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.12 hr		Drug Reactions: Definition and types. Detection and reporting methods.	
Unit-4:Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance12 hrUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.12 hr		Severity and seriousness assessment. Predictability and preventability	
Unit-4:Basic aspects, terminologies and establishment of Pharmacovigilance History and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance12 hrUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.12 hr		assessment, Management of adverse drug reactions; Terminologies of ADR.	
<ul> <li>unit-4:</li> <li>unit-4:</li> <li>unit-4:</li> <li>and progress of Pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance</li> <li>Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.</li> </ul>		Basic aspects, terminologies and establishment of Pharmacovigilance History	12 hr
<ul> <li>Unit-4: Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance</li> <li>Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.</li> </ul>		and progress of Pharmacovigilance, Significance of safety monitoring,	
Unit-4:drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance12 hrUnit-5:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.10 hr		Pharmacovigilance in India and international aspects, WHO international	
<ul> <li>Unit-4: evaluation of medication safety, Establishing Pharmacovigilance centres in Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance</li> <li>Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.</li> </ul>		drug monitoring programme, WHO and Regulatory terminologies of ADR,	
<ul> <li>Hospitals, Industry and National programmes related to Pharmacovigilance. Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical Pharmacist in Pharmacovigilance</li> <li>Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.</li> </ul>	Unit-4:	evaluation of medication safety, Establishing Pharmacovigilance centres in	
Incorpland, inductry inductry in positive in program in the progr		Hospitals Industry and National programmes related to Pharmacovigilance.	
Pharmacist in Pharmacovigilance         Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.		Roles and responsibilities of Pharmacist, Community Pharmacist and Clinical	
Unit-5:Methods, ADR reporting and tools used in Pharmacovigilance International classification of diseases, International Non- proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.12 hr		Roles and responsionnes of Financial, Communy Financial and Community	
Unit-5: Clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.		Mathada ADR reporting and tools used in Pharmacovigilance International	12 hr
Unit-5: Classification of diseases, international root-proprietary names for diags, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.		Methods, ADX reporting and tools used in r narifactory names for drugs	
Unit-5: Passive and Active survemance, Comparative observational studies, rargeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.		classification of diseases, international Non- proprietary names for drugs,	
Unit-5: clinical investigations and vaccine safety surveitlance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.	Unit-5:	Passive and Active surveinance, Comparative observational studies, Targeted	
system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.		clinical investigations and vaccine safety surveillance. Spontaneous reporting	
reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.		system and Reporting to regulatory authorities, Guidelines for ADRs	
for evaluating medication safety data.		reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods	
and the second		for evaluating medication safety data.	<u> </u>
		S. S. Martin	62

PRINCIPA

406 APREM

CATHANKS

.

Unit-6:	Pharmacoepidemiology, pharmacoeconomics, safety pharmacology	12 m
	Text books 1. Handbook of clinical Research. Julia Lloyd and Ann Raven Ed. Churchill	
	<ol> <li>Principles of Clinical Research edited by Giovanna di Ignazio, Di Giovanna and Haynes.</li> </ol>	
	<ul> <li>References Books</li> <li>1. Central Drugs Standard Control Organization- Good Clinical Practices, Guidelines for Clinical Trials on Pharmaceutical Products in India. New Delhi: Ministry of Health;2001.</li> <li>2. International Conference on Harmonization of Technical requirements for registration of Pharmaceuticals for human use. ICH Harmonized Tripartite Guideline. Guideline for Good Clinical Practice.E6; May 1996.</li> <li>3. Ethical Guidelines for Biomedical Research on Human Subjects 2000. Indian Council of Medical Research, New Delhi.</li> <li>4. Textbook of Clinical Trials edited by David Machin, Simon Day and Sylvan Green, March 2005, John Wiley and Sons.</li> <li>5. Clinical Data Management edited by R K Rondels, S A Varley, C F Webbs. Second Edition, Jan 2000, Wiley Publications.</li> </ul>	
	r	
	StinMER COL	15:0.
	PRINCIP	IN SI
	Lunger	The second

. .

M. Pharm- Semester-II						
COURSE		T-0				
CODE	PHARMACOLOGY PRACTICAL - II	P-1				
MPL205P	РПАКМАССЕССТ ГНАТСТА	C-(				
Course outer	amag					
Jourse outer	On Completing the Course, the student will be:					
	<b>CO1</b> : Understanding the concept of bioassay in experimental					
	pharmacology					
	CO2: Applying various techniques to determine the strength of drugs in					
	isolated tissues					
	CO3. Predicting the dose toxicity studies					
	CO1: Evaluating the various effect of drugs on different animal models					
	CO4: Evaluating the various encer of drugs on different					
Course Con	tent					
	1. To record the DRC of agonist using suitable isolated tissues preparation.					
	2. To study the effects of antagonis/potentiating agents on Dice of agonise					
	using suitable isolated tissue preparation.					
	3. To determine to the successful of unknown sample by matching bloassay by					
	To determine to the strength of unknown sample by interpolation bioassay					
	4. To determine to the strength of unknown sample by interpotation of outsury					
	5 To determine to the strength of unknown sample by bracketing bioassay by					
	using suitable tissue preparation					
	6 To determine to the strength of unknown sample by multiple point bioassay					
	by using suitable tissue preparation.					
	7. Estimation of PA2 values of various antagonists using suitable isolated					
	tissue preparations.					
	8. To study the effects of various drugs on isolated heart preparations					
	9. Recording of rat BP, heart rate and ECG.					
	10. Recording of rat ECG					
	11. Drug absorption studies by averted rat ileum preparation.					
	12. Acute oral toxicity studies as per OECD guidelines.					
	13. Acute dermal toxicity studies as per OECD guidelines.					
	14. Repeated dose toxicity studies- Serum biochemical, naematological, unne					
	15 Drug putgenicity study using mice hone marrow chromosomal aberration					
	15. Drug indiagementy study using infee bone-marrow emonosomal aberration					
	16 Protocol design for clinical trial (3 Nos)					
	17. Design of ADR monitoring protocol.					
	18. In-silico docking studies. (2 Nos.)					
	19. In-silico pharmacophore-based screening.					
	20. In-silico QSAR studies.					
*	21. ADR reporting					
	Reference Books					
Carlo Month	1. Fundamentals of experimental Pharmacology-by M.N.Ghosh					
	2. Trand book of Experimental Pharmacology-S.K.Kulakarni					
	4. Bioassay Techniques for Data Development by Attern Data					
	Iobal choudhary and William Thomsen					
	5. Applied biopharmaceutics and Pharmacokinetics by Leon Sharpal and					
	Andrew B.C.Yu.					
	6. Handbook of Essential Pharmacokinetics, Pharmacodynamics and					
	Drug Metabolism for Industrial Scientists.					
		-				
L	NAMEERCOLI	Fred				
	1 Mil	K				
		4				

PRINCIPAL

\* M.JRADAP

COURSE CODE: MRM301T	M. Pharm- Semester-III RESEARCH METHODOLOGY & BIOSTATISTICS	L-4 T-0 P-0
1.	General Research Methodology: Research, objective, requirements, practical difficulties, review of literature, study design, types of studies, strategies to eliminate errors/bias, controls, randomization, crossover design, placebo, blinding techniques.	C-4 12hr
2	Biostatistics: Definition, application, sample size, importance of sample size, factors influencing sample size, dropouts, statistical tests of significance, type of significance tests, parametric tests (students "t" test, ANOVA, Correlation coefficient, regression), non-parametric tests (wilcoxan rank tests, analysis of variance, correlation, chi square test), null hypothesis, P values, degree of freedom, interpretation of P values.	12hr
3	Medical Research: History, values in medical ethics, autonomy, beneficence, non-maleficence, double effect, conflicts between autonomy and beneficence/non-maleficence, euthanasia, informed consent, confidentiality, criticisms of orthodox medical ethics, importance of communication, control resolution, guidelines, ethics committees, cultural concerns, truth telling, online business practices, conflicts of interest, referral, vendor relationships, treatment of family members, sexual relationships, fatality	12hr
4	CPCSEA guidelines for laboratory animal facility: Goals, veterinary care, quarantine, surveillance, diagnosis, treatment and control of disease, personal hygiene, location of animal facilities to laboratories, anesthesia, euthanasia, physical facilities, environment, animal husbandry, record keeping, SOPs, personnel and training, transport of lab animals	12hr
5	Declaration of Helsinki: History, introduction, basic principles for all medical research, and additional principles for medical research combined with medical care.	12hr
	<ol> <li>Cooper &amp; Schindler, Business Research Methods, Tata McGraw Hill.</li> <li>Saunders, Research Methods for Business Students, Pearson Education</li> <li>Allen T Harrell, New Methods in Social Science Researchs, Praeger Publishers, New York</li> <li>Beri, G.C., Statistics for Management, Tata MacGraw-Hill</li> <li>Chandan J. S., Statistics for Business and Economics, Vikas Publications.</li> <li>Broota, K.D., Experimantal Designs in Behavioural Research, New Age International</li> <li>Singh A. K., Test Measurement and Research Methods in Behaviours Sciences, BhartiBhawan</li> <li>Joyce Cox &amp; Polly Urban, Microsoft Office, Galgotia Publishing</li> <li>Sinha P.K., Computer Fundamentals, BPB Publishing.</li> </ol>	
*1	atest editions of all the suggested books are recommended.	ar x

MICIPI

COURS CODE: MRM302	E M. Pharm- Semester-III T PHARMACOECONOMICS	L-3 T-0 P-0
Unit-1	Basic Concepts <ul> <li>Introduction to Pharmacoeconomics</li> <li>History, evolution, objective and importance</li> <li>Relationship of Pharmacoeconomics to other research</li> </ul>	C-3 12 hr
Unit-2	<ul> <li>Types of Pharmacoeconomic studies</li> <li>Pharmacoeconomic evaluation: Basic outline only</li> <li>Measuring and estimating cost: Costing terms, timing adjustment cost, resource for cost estimation</li> <li>Cost minimization analysis (CMA)</li> <li>Cost effectiveness analysis (CEA): Presentation of cost effective analysis, cost effectiveness grid, cost effectiveness plane, intermediate versus primary outcomes and efficacy versus effectiveness</li> <li>Cost utility analysis (CUA)</li> <li>Cost benefit analysis (CBA): Advantages and disadvantages, calculating result of cost and benefits</li> </ul>	18 hr
Unit-3	Case studies     Software Text books:	12 hr
]	<ol> <li>Pharmacoeconomics-From Theory to Practice. Editor.: <u>Renee J. G. Arnold</u>- 2nd Edition. Pub.: CRC Press, 2021.</li> <li>Essentials of Pharmacoeconomics. Editor.: Karen L. Rascati – 2nd Edition. Pub.: Lippincott Williams &amp; Wilkins, 2014.</li> <li>Pharmacoeconomics. Authors: Tom Walley, Alan Haycox, Angela Boland- 1st Edition. Pub.: Churchill Livingstone (Elsevier), 2003.</li> </ol>	

and Cipi

31

COURSE CODE: MRM303T	M. Pharm- Semester-III I BLOCKCHAIN TECHNOLOGY IN PHARMACEUTICAL I INDUSTRY C							
Unit-1	Basic concepts of Blockchain technology Principal & types of Blockchain technology, Advantages of Blockchain technology, rationale of Blockchaintechnology, Key elements in Blockchain technology; Blockchain tools, Blockchain platforms, applications. Importance of Blockchain to India: Indian economy and Blockchain.	12 hr						
Unit-2	Blockchain Technology in Healthcare Blockchain for management of patient consent and data access permissions, Blockchain for managing medical and pharmaceutical supply chains, Blockchain in inventory management, Blockchain in handling counterfeit drugs, Blockchain in Pharmaceutical R & D, Blockchain in Clinical trials, Policy considerations for deploying Blockchain.Pharma Opportunities with Blockchain, Companies Using a Blockchain Solution in Healthcare and Pharma.	12 hr						
Unit-3	Blockchain Technology in environment protection Blockchain Technology and Environmental Sustainability, Blockchain in tracking the carbon footprint, recycling program on the Blockchain, Blockchain based energy system, Implications for the European environment, Implications for environmental policy in Europe							
Unit-4	Blockchain Technology for Food & Cosmetics Industry Blockchain and cosmetic industry, Blockchain and Food Industry.	6 hr						
	<ol> <li>Text books         <ol> <li>Blockchain in Healthcare: Innovations that Empower Patients, Connect Professionals and Improve Care. Author: Vikram Dhillon , John Bass, Max Hooper, David Metcalf and Alex Cahana- Ist Edition. Pub.: Productivity Press, 2018.</li> <li>Blockchain for Healthcare Systems. Author: Pankaj Bhatt, Suruchi Singh, Satish Kumar Sharma, Vipin Kumar- 1st Edition. Pub.: CRC Press, 2021.</li> <li>Blockchain Technology and Applications. Editor: Pethuru Raj, KavitaSaini and ChellammalSurianarayanan Ist Edition. Pub.: Auerbach Publications, 2021.</li> </ol> </li> </ol>							
	*Latest editions of all the suggested books are recommended.							



COURSE CODE:	COURSE CODE: ARM304T DIGITAL THERAPEUTICS AND CURATIVE THERAPIES				
Unit-1	<b>Digital Therapeutics</b> Digital drugs/Digital Therapeutics, History of Digital Therapeutics, Digital Health, Relationship between Digital Health, Digital Medicine, and Digital Therapeutics, mechanism of action, regulatory aspects, Barriers in the Adoption of Digital Therapeutics, Digital therapeutics and Practice of Primary Care, Prescription Digital Therapeutics, Non-Prescription Digital Therapeutics, Wellness Apps (technically not a Digital therapeutic), Standalone digital therapeutics, Smart Ancillary Devices, Companion apps. Potential applications of Digital Therapeutics.	18 hr			
Unit-2	Curative Therapies Curative Therapeutics, Curative Therapy: Gene therapy, Cell Therapy; Curative therapy for Brest Cancer, Colorectal Cancer, Lung Cancer, Sickle Cell Disease, Prostate Cancer.	12 hr			
Unit-3	Precision Interventions Robotic Surgery, Nanotechnology, 3D printing and tissue engineering	6 hr			
Unit-4	Personalized or customized treatment Tailored dosing, Tailored drug regims	6 hr			
	<ol> <li>Text Books:         <ol> <li>The Digital Health Revolution. Author: Kevin Percau, Editor: Barry Lenson-Ist Edition. Pub.: Transcendit Health, 2019.</li> <li>Digital Health- Meeting Patient and Professional Needs Online. Author: Barrie Gunter-Ist Edition. Pub.: Taylor &amp; Francis Inc, 2006.</li> <li>Goodman and Gilman's- The Pharmacological Basis of Therapeutics. Author Laurence Brunton, Bjorn Knollmann and Randa Hilal-Dandan- 13th Edition. Pub. McGraw Hill, 2017.</li> </ol> </li> </ol>				
	*Latest editions of all the suggested books are recommended.				



-

COURSE CODE: MRM305T	M. Pharm- Semester-III BIOSIMILARS	L-3 T-0 P-0 C-3
Unit-1	Basic Concepts Biologic Product, Biosimilar Product, Biobetters, Noncomparable biotherapeutics ('intended copies'), difference between Comparability and biosimilarity, Difference between generic drugs and biosimilars, Critical quality attributes of biosimilars, Role of confirmatory clinical studies in biosimilar development, Extrapolation across clinical indications: rationale & scientific justification, Importance of immunogenicity assessment of biosimilars, Interchangeability & switching from reference (originator) products to biosimilars, Practical guidance on the use of biosimilars in clinical practice.	24 hr
Unit-2	Regulatory Perspectives Regulatory requirement for biosimilars (EMA, FDA & WHO), Selection of reference products, Manufacturing of Biosimilars, establishment of analytical similarity of biosimilars, the role of comparative <i>in vivo</i> non clinical studies, comparative immunogenicity assessment, clinical efficacy and safety similarity.	12 hr
Unit-3	Important Clinical applications of Biosimilars Biosimilars in rheumatology, breast cancer, colorectal cancer and nephrology.	6 hr
	<ol> <li>Text books         <ol> <li>Biologics, Biosimilars, and Biobetters: An Introduction for Pharmacists, Physicians and Other Health Practitioners. Editor: Iqbal Ramzan. Pub.: Wiley, 2021.</li> <li>Biosimilars-Design and Analysis of Follow-on Biologics. Editor: Shein- Chung Chow- 1st ed. Pub.: CRC Press, 2019.</li> <li>Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development. Editor: Hiten J. Gutka, Harry Yang and ShefaliKakar- 1st ed.Pub.:Springer, 2018.</li> </ol> </li> </ol>	
	*Latest editions of all the suggested books are recommended.	





Scanned with CamScanner

COURSE CODE: MRM309T	OURSE M. Pharm-Semester-III ODE: ENTREPRENEURSHIP SKILL DEVELOPMENT RM309T								
	Course Outcomes:								
	<b>CO1-</b> Recognizing an entrepreneur's DNA and evaluating their strengths and flaws from an entrepreneurial standpoint.								
	CO2-Developing and Inspiring people to start their businesses by highlighting successful entrepreneurs								
Unit-1:	<b>Introduction to Entrepreneurship:</b> Meaning and concept of entrepreneurship, the history of entrepreneurship development; the skills/ traits required to be an entrepreneur; Creative and Design Thinking; the entrepreneurial decision process.	14 Hrs							
Unit-2:	Entrepreneurial success stories; Role of innovation in entrepreneurship; technical entrepreneurship through incubation; objectives of technology business incubation; Innovative ideas; SWOT analysis.	14 Hrs							
	Reference Books								
1	Emiel L. Eijdenberg, Neil_Thompson. Entrepreneurs' Creative Responses to Institutional Challenges. Emerald Publishing Limited.								
2	Michael WP. Fortunato, Theodore R. Alter. Entrepreneurship, Community and Community Development. Taylor & Francis Ltd.								



COURSE CODE: MRM310T	M. Pharm-Semester-III INTELLECTUAL PROPERTY RIGHTS						
	Course Outcomes:						
	CO1- Understanding the basic concepts of Intellectual property Rights						
	<b>CO2-</b> Understanding and identifying criteria to fit one's intellectual work in particular IPRs.						
Unit-1:	Introduction to intellectual property rights; acts governing the various IP rights; trademark law in India; industrial designs; trade secret; copyright	14 Hrs					
Unit-2:	Role of IPR in pharmaceutical industry growth; patent; IPR of computer software; regulation of pharmaceutical sector; National Pharmaceutical Pricing Authority (NPPA).	14 Hrs					
	Reference Books						
1	Rupinder Tewari, Mamta Bhardwaj. Intellectual Property- A Primer for Academia. Publication Bureau, Panjab University Chandigarh-160014, India						
2	Asha Vijay Durafe, Dhanashree K. Toradmalle. Intellectual Property Rights. Wiley.						



COURSE CODE: MRM311T	M. Pharm-Semester-III I BUSINESS MODEL INNOVATION (						
	Course Outcomes:						
	<b>CO1-</b> Understanding the basic needs to create a business model and building a prototype.						
	<b>CO2-</b> Acquiring the skills and knowledge related to the various phases in the venture creation process.						
Unit-1:	<b>Preparation of Business model/Plan:</b> Meaning and significance of a business plan; components of a business plan and feasibility study; MVP (Minimum Viable Product); The importance and diversity of business model; components of an effective business model; core strategy and strategic resources.	14 Hrs					
Unit-2:	<b>Development and validation of Business Processes:</b> Introduction and importance of ventures; visioning for the venture; digital presence for ventures; Bank Loans and key elements of raising money for a new venture.	14 Hrs					
	Reference Books						
1.	Massa, L. and Tucci, C.L., 2013. Business model innovation. The Oxford handbook of innovation management, 20(18), pp.420-441.	?					
2.	Burgelman, R.A. and Sayles, L.R., 1988. Inside corporate innovation. Simon and Schuster.	e					



COURSE	M. Pharm-Semester-III	L-2					
CODE:	PRINCIPLES OF MANAGEMENT						
MRM312T							
	Course Outcomes:	C-2					
	CO1- Understanding de Calendaria	-					
	correction of the fundamental exposure to the basic						
	concepts of management and demonstrating management's roles,						
	skills, and functions.						
	CO2- Analyze the effective application of management and staffing						
	to diagnose and solve organizational problems and develop an						
	optimal managerial decision.						
Unit-1:	Management: definitions, types of managers; evolution of	14 Hrs					
	management thought; principles of management; functions of						
	management; social responsibility of management; challenges of						
	management; managerial ethics.						
	Planning- Nature, purpose and importance of planning; principles of						
	the organization; formal and informal organization; types of						
	organization structure						
Jnit-2:	Staffing: Concept, nature, importance of staffing; concept of	14 Hrs					
	knowledge worker; Staff directing, concept, nature, importance;						
	Staff control techniques: Leadership concept nature importance:						
	decision making.						
	Reference Books						
1.	Koontz & O'Donnel, Essentials of Management, Tata McGraw	·····					
	Hill, New Delhi						
2.	Louis A Allen, Management and Organization, McGrawHill, New						
	York						
3.	Peter F Drucker, The Practice of Management, McGraw Hill, New						
	York						



# **Examinations/Assessments**

Table 3 &3.1 depicts the scheme for internal and external assessment.

# Table 3: Schemes for internal assessments and end semester

S.No	Subject Code	Subject Subject Name Code	Credit			Total	Credit				
			IIIS./ WEEK		Sessi (Marks	onal Ex: s distrib	ution)	End Sei	ation	Marks	Points
				C Contin		tinuous	TOT			1	
				Т	mod	e	AL	Marks	Duration		
				*	ST/	At		Marks	(hrs.)		
				SEN	MEST	TER I		1			
1	MPL101T	Modern	4	15	02	08	25	75	3	100	4
		Pharmaceutical									
		Analytical									
		Techniques		1		-					
2	MPL102T	Advanced	4	15	02	08	25	75	3	100	4
		Pharmacology-I			1.062473	0.00000	erestesse	1.0000			
3	MPL103T	Pharmacological	4	15	02	08	25	75	3	100	4
		and									
		Toxicological									
		Screening									
		Methods-I									
1	MPL104T	Cellular and	4	15	02	08	25	75	3	100	4
		Molecular			1		1	10000	1.079		
		Pharmacology									
5	MPL105P	Pharmacology	12	30	10	10	50	100	6	150	6
		Practical I									
5	MPL106	Seminar	7						<u></u>	100	4
		/Assignment									
		Total	35							650	26
			S	EM	IEST	ER II					
	MPL201T	Advanced	4	15	02	8	25	75	3	100	4
		Pharmacology-			- 2	1					
		II									
	MPL202T	Pharmacological	4	15	02	8	25	75	3	100	4
		and									
		Toxicological									
	_	Screening									
		Methods-II									
	MPL203T	Principles of	4	15	02	8	25	75	3	100	4
		Drug Discovery									
	MPL204T	Clinical	4	15	02	8	25	75	3	100	4
		Research &									
		Pharmacovigila									
		nce									
	MPL205P	Pharmacology	12	30	10	10	50	100	6	150	6
		Practical II									
	MPL206	Seminar	7							100	4
	ana seberna da 19	/Assignment									
		Total	35							650	26



39

inserved assessments and end semester (initia de 17 di bemester)							icsici (iii	ind de 1 v													
				Evaluation Scheme						- Total											
100 000	Subject Code	Subject Subject Name Credit			Sessio	nal Ex	emester	mester Marks													
S. No				Credit (Marks distribution)					ination		Credit										
	cour		hrs./Week		Contin	uous		Marks	Duration		Points										
				CT#	mod	le	TOTAL		(hrs.)		4										
			CE	MEC	ST	At															
		Doronnah	SE	MES	TER			·		1	T										
1	MRM301T	Methodology and			0.0					1.00											
		Biostatistics*	4	15	02	08	25	15	3	100	4										
	MRM302T	Pharmacoeconomics																			
		Blockchain	1																		
	MDM202T	Technology in																			
	511115051	Pharmaceutical																			
2		Industry	3	15	02	08	25	50	2	75	1										
		Digital Therapeutics				0.0	2.5	20	2												
	MRM304T	and Curative																			
		Therapies	ingers.	1																	
	MRM305T	Biosimilars	1																		
3	MRM306	Journal Club	1			-	25			25	1										
	MRM307	Discussion /						-		50											
4		Presentation	2				50		-												
		(Proposal		-	-						2										
		Presentation)																			
5	MRM308	Research Work	28		-	-	-	350	1	350	14										
	MENIMOT	Entrepreneurship																			
		Skill Development																			
	MRM310T	Intellectual Property		10	01	04		35	2												
	Michiotot	Rights																			
	MRM311T	Business Model	2	10			15			50	2										
		Innovation		1																	
6	MPM312T	Principles of																			
	MIKM5121	Management																			
		Total	40							650	26										
			SE	MES	TER	IV															
1	MRM401	Journal Club	1	-	-	-	25	-		25	1										
		Discussion /																			
2	MRM402	Presentation (Final	3				75			25											
-		Presentation (Final			· ·		15	· ·		15	5										
		resentation																			
3	MRM403	Research Work &	31					400	1	400	16										
		Colloquium								400	10										
		Total	35							500	20										

# Table 3.1: Schemes for internal assessments and end semester (IIIrd & IVth Semester)

#### \*\*\*\*\*\*

PRINCIPAI 2-4-15-